Abstract
A new transfection-free helper system supports a high-yield manufacturing process for recombinant adeno-associated viruses (rAAV), raising the bar for producing safe, high-quality viral vectors at scale.
To learn more about TESSA, evaluate it or discuss partnering to explore this technology with OXGENE, a WuXi Advanced Therapies Company, the advanced therapies business unit of WuXi AppTec, please visit OXGENE.com/TESSA.
The TESSA paper can be found here.
View the paper in full here.